Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a novel and tolerable office-based treatment method,
sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to
Hereditary Hemorrhagic Telangiectasia (HHT) disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute